Comparing the current results to its competitors, Insulet reported Revenue increase in the 1 quarter 2026 by 33.87 % year on year. The sales growth was above Insulet's competitors' average revenue growth of 9.66 %, achieved in the same quarter.
Insulet Corporation Net Income in the 1 quarter 2026 grew year on year by 157.34%, while most of its competitors have experienced a contraction in net income by -41.68 %.
Insulet's Comment on Competition and Industry Peers
The diabetes medical device market is competitive and evolving, driven by new product developments. The Omnipod platform operates in the insulin delivery segment, competing with companies that offer products and supplies for multiple daily injection (MDI) therapy, including smart pens. It also competes with manufacturers of insulin pumps, encompassing both tubed pump providers and developers of insulin patch pumps and other treatment methods for insulin-dependent diabetes. Additionally, there is recognition of the growing use of GLP-1 products, which may delay the progression of type 2 diabetes in obese patients.
November 1, 2024
As November unfolds, Insulet Corporation, a pioneer in tubeless insulin pump technology, is poised to make significant strides in enhancing diabetes management and raising awareness during National Diabetes Awareness Month and World Diabetes Day. The company is renowned for its innovative Omnipod brand of products, which are transforming the landscape of insulin delivery for individuals managing diabetes.Recognizing that diabetes management entails a myriad of daily decisions often stressful and overwhelming Insulet is taking proactive measures to support individuals navigating these complexities. Through a series of initiatives, the company aims to foster greater understanding and awareness of diabetes, ult...
August 8, 2024
Insulet Corporation, a leader in tubeless insulin pump technology, has shared its impressive financial and clinical performance for the second quarter of 2024, signaling its burgeoning influence in diabetes management. With a reported revenue of $488.5 million, representing a 23.2% increase year-over-year, the company has not only exceeded its guidance expectations but also solidified its position within the fast-evolving diabetes care market. Financial Growth: A Resounding Success The financial results underline a robust demand for Insulet s products, particularly the Omnipod insulin delivery systems, during a period when healthcare companies are navigating economic challenges. This revenue growth demonstra...
June 23, 2024
In a transformative stride for diabetes management, Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, has presented unequivocally positive results from its pivotal Omnipod 5 Automated Insulin Delivery System (Omnipod 5) trial for type 2 diabetes. Amidst the grandeur of the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida, Insulet showcased data that promises to elevate clinical outcomes and enhance the quality of life for individuals with type 2 diabetes. Concurrently, Insulet has launched the Omnipod 5 system in the United Kingdom and the Netherlands, marking a significant expansion in their mission to revolutionize diabetes care globa...
June 22, 2024
Insulets SECURE-T2D Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 DiabetesACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced positive results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) type 2 diabetes pivotal trial. These results were shared at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida. The landmark study assessed the impact of automated insulin delivery (AID) in a diverse group of people with type 2 diabetes, highlighting the promising outcomes and improved quality of life with the use o...
June 20, 2024
Insulet s Omnipod 5 with Expanded Sensor Integrations Now Available in the UK and the Netherlands: Revolutionizing Insulin Management for Diabetes PatientsACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the pioneer in tubeless insulin pump technology with its Omnipod brand, is thrilled to announce the full commercial launch of Omnipod 5 in the United Kingdom and the Netherlands. Omnipod 5, the next-generation insulin management system, is designed for individuals aged two years and older with type 1 diabetes. With its compatibility with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, this innovative device aims to transform the lives of diabetes patients in these...
February 7, 2024
Insulet s Omnipod 5 Receives CE Mark Approval for Integration with Abbott FreeStyle Libre 2 Plus Sensor: A Major Breakthrough for Type 1 Diabetes Management ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the renowned leader in tubeless insulin pump technology with its Omnipod brand, announced a significant development today. The Company has successfully obtained CE mark approval under the European Medical Device Regulation for the compatibility of the Abbott FreeStyle Libre 2 Plus sensor with Insulet s Omnipod 5 Automated Insulin Delivery System. This groundbreaking integration promises to revolutionize diabetes management for individuals aged two years and older with type 1 diabetes.The integration of t...
Dexcom Incs business model focuses on developing and selling continuous glucose monitoring systems for diabetes management. Their products provide real-time glucose level tracking, enabling users to better manage their condition through data-driven insights.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Modular Medical Inc operates with a business model focused on designing and manufacturing modular medical units, offering cost-effective and customizable solutions for healthcare providers looking to expand their facilities rapidly and efficiently. They aim to deliver innovative and turnkey solutions that can be easily deployed and scaled to meet the specific needs of their clients.
Tandem Diabetes Care Inc is a medical device company that specializes in designing, manufacturing, and marketing insulin pumps. Their business model revolves around developing and selling technologically advanced insulin delivery systems to improve the quality of life for individuals with diabetes. By constantly innovating and focusing on customer needs, Tandem Diabetes Care Inc aims to capture a significant portion of the insulin pump market and establish itself as a trusted leader in the industry.
Sources:
Insulet Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Insulet Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
